Drugs / HM-002-1005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06498284 | Apr → Sep 2024 | type 2 diabetes mellitus | Hua Medicine Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-30 | Hua Medicine Limited | Results Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate huamedicine.com ↗
The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-30 | Hua Medicine Limited | Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate huamedicine.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM-002-1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06498284 ↗ |
| Route | Oral | “HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets” NCT06498284 ↗ |